EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications

Emanuela Germanà iD, Ludovica Pepe, Cristina Pizzimenti iD, Mariagiovanna Ballato iD, Francesco Pierconti, Giovanni Tuccari iD, Antonio Ieni, Giuseppe Giuffrè, Guido Fadda, Vincenzo Fiorentino iD, Maurizio Martini iD

International Journal of Molecular Sciences · 19.06.2024 · 25 (12) · 6750

DOI: 10.3390/ijms25126750 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.06.2024. Verfasst von Emanuela Germanà und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The management of advanced bladder carcinoma involves a multidisciplinary approach, but the prognosis remains poor for many patients. The immune system plays a crucial role in this disease, influencing both tumor development and response to treatment, and exploiting the immune system against the tumor can be a valuable strategy to destroy neoplastic cells. This is the biological principle underlying Bacillus Calmette–Guérin (BCG) use and, more recently, immune checkpoint inhibitors (ICIs), like PD-1 (programmed death-1)/PD-L1 (programmed death-ligand 1) inhibitors. In fact, one of the best studied immune checkpoints is represented by the PD-1/PD-L1 axis, which is a well-known immune escape system adopted by neoplastic bladder cells. PD-L1 expression has been associated with a higher pathologic stage and has shown prognostic value in bladder carcinoma. Interestingly, high-grade bladder cancers tend to express higher levels of PD-1 and PD-L1, suggesting a potential role of such an axis in mediating disease progression. Immunotherapy with PD-1 and PD-L1 inhibitors has therefore emerged as a valuable treatment option and has shown efficacy in advanced bladder cancer patients, with high PD-L1 expression levels associated with better treatment responses. Our review aims to provide a comprehensive overview of the role of PD-L1 in advanced bladder cancer, focusing on its implications for treatment decisions and the prediction of treatment response. Overall, our work aims to contribute to the understanding of PD-L1 as a predictive biomarker and highlight its role in shaping therapeutic approaches for advanced bladder cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsB7-H1 AntigenHumansPrognosisBiomarkers, TumorImmunohistochemistryImmune Checkpoint InhibitorsImmunotherapyProgrammed Cell Death 1 Receptor

Stichwörter der Autor:innen

PD-1/PD-L1 axisbladder carcinomaimmune systemimmunotherapy

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, TumorImmune Checkpoint InhibitorsProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, 98125 Messina, Italy.
  • Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", University of Messina, 98125 Messina, Italy.
  • Pathology Unit, Papardo Hospital, 98158 Messina, Italy.
  • Department of Women, Children and Public Health Sciences, Catholic University of the Sacred Heart, Agostino Gemelli IRCCS University Hospital Foundation, 00168 Rome, Italy.

ORCID-Profile: Emanuela Germanà, Cristina Pizzimenti, Mariagiovanna Ballato, Giovanni Tuccari, Vincenzo Fiorentino, Maurizio Martini

Zitieren

APA

Germanà, E., Pepe, L., Pizzimenti, C., Ballato, M., Pierconti, F., Tuccari, G., Ieni, A., Giuffrè, G., Fadda, G., Fiorentino, V., & Martini, M. (2024). Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. International Journal of Molecular Sciences, 25(12), 6750. https://doi.org/10.3390/ijms25126750

Vancouver

Germanà E, Pepe L, Pizzimenti C, Ballato M, Pierconti F, Tuccari G, et al. Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications. International Journal of Molecular Sciences. 2024;25(12):6750. doi:10.3390/ijms25126750

BibTeX
@article{German2024,
  author = {Germanà, Emanuela and Pepe, Ludovica and Pizzimenti, Cristina and Ballato, Mariagiovanna and Pierconti, Francesco and Tuccari, Giovanni and Ieni, Antonio and Giuffrè, Giuseppe and Fadda, Guido and Fiorentino, Vincenzo and Martini, Maurizio},
  title = {Programmed Cell Death Ligand 1 (PD-L1) Immunohistochemical Expression in Advanced Urothelial Bladder Carcinoma: An Updated Review with Clinical and Pathological Implications},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {12},
  pages = {6750},
  doi = {10.3390/ijms25126750}
}
Kostenlos starten →